Durvalumab was associated with a 27% reduction in the risk for death compared with placebo in the phase 3 ADRIATIC trial.
The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody, Imfinzi (durvalumab), to ...
AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...
AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...
The approval of durvalumab, based on data from the phase 3 ADRIATIC study, offers a new standard of care for patients with ...
A new trial finds that cetuximab outperforms durvalumab as a second-line treatment in patients who cannot tolerate cisplatin.
AstraZeneca’s IMFINZI® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...
The monoclonal antibody cetuximab (Erbitux) was more effective than a newer drug, the immune checkpoint inhibitor medicine ...
Patients experienced similar safety and efficacy if they received first-line or later-line treatment for unresectable ...
Accompanying these findings is a call for refined treatment strategies that have potential to better outcomes among patients ...
The agency granted approval to durvalumab for the treatment of a subset of patients with limited-stage small cell lung cancer ...
Based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo AstraZeneca's IMFINZI (durvalumab) has been approved in the US for the treatment of adult ...